title: In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
abstract: We investigated the in-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae, and compared it with ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin and minocycline. AM-1155 was the most potent agent in vitro of the quinolones tested. Its pre-treatment minimal inhibitory concentrations for 90% of the 41 strains (MIC90) was 0.06 mg/L. In contrast, pre-treatment MIC90 values for ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin, and minocycline were 1, 1, 2, 0.5, 0.0156, and 0.5 mg/L, respectively. Post-treatments MIC90s, which may reflect mycoplasmacidal potency, of AM-1155, ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin and minocycline were 0.125, 1, 2, 4, 0.5, 0.125 and 4 mg/L, respectively. In-vitro activities of antimicrobial agents were assessed in an experimental pulmonary infection model in Syrian golden hamsters. AM-1155 was the most effective agent among five antimicrobial agents (AM-1155, ofloxacin, tosufloxacin, erythromycin, minocycline) tested in terms of reduction in viable M. pneumoniae cells and in reducing macroscopic lung lesions. These results suggest that AM-1155 will be a useful antimicrobial agent for the treatment of M. pneumoniae infections.
authors.affiliation: Department of Laboratory Medicine, Nagasaki University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ishida
authors.forename: M
authors.initials: M
authors.lastname: Kaku
authors.forename: K
authors.initials: K
authors.lastname: Irifune
authors.forename: R
authors.initials: R
authors.lastname: Mizukane
authors.forename: H
authors.initials: H
authors.lastname: Takemura
authors.forename: R
authors.initials: R
authors.lastname: Yoshida
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Usui
authors.forename: K
authors.initials: K
authors.lastname: Tomono
authors.forename: N
authors.initials: N
authors.lastname: Suyama
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D006224:Cricetinae; D004195:Disease Models, Animal; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D008168:Lung / Q000737:chemistry; D008297:Male; D008647:Mesocricetus; D008911:Minocycline / Q000494:pharmacology; D009177:Mycoplasma pneumoniae / Q000187:drug effects*; D010879:Piperazines / Q000032:analysis / Q000494:pharmacology*; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy; D015363:Quinolones / Q000032:analysis / Q000494:pharmacology*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; D004917:Erythromycin; D008911:Minocycline; D000077734:Gatifloxacin